You are here
Achaogen Reports Third Quarter 2018 Financial Results and Provides Corporate Update
-- Company provides update on ZEMDRITM commercialization and launch --
-- Conference call today at 8:30 a.m. Eastern Time --
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today reported financial results for the third quarter ended September 30, 2018, and provided an update on its commercial and corporate activities.
“Momentum for ZEMDRI continues to build and we are pleased with the interest we are seeing for the product as a result of ZEMDRI’s strong clinical data, differentiated profile, and versatility across inpatient and outpatient treatment settings,” said Blake Wise, Achaogen’s Chief Executive Officer. “We also advanced other important corporate priorities, including the submission of a Marketing Authorization Application for plazomicin to the European Medicines Agency while streamlining operations and reducing expenses.”
Recent Highlights and Upcoming Milestones
- ZEMDRI Launch Update: The launch focus continues to be the education of physicians on the clinical profile of ZEMDRI and building the foundation to support product use across the hospital and outpatient settings. The commercial organization continues to build momentum on key leading indicators including: formulary review and approval, orders of antibiotic susceptibility testing materials and customer readiness for therapeutic drug management testing. ZEMDRI revenues for the quarter represent approximately two months of product sales prior to broad formulary approval or the availability of the NTAP supplementary reimbursement, which went into effect on October 1st. During the quarter, ZEMDRI achieved net revenues of $291,000 and, to date, 60% of use has been in the outpatient setting.
- European Marketing Authorization Application (MAA): On October 15, 2018, Achaogen announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for plazomicin seeking approval for the following indications:
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Bloodstream infections (BSI) due to certain Enterobacteriaceae and
- Infections due to Enterobacteriaceae in adult patients with limited treatment options
- NTAP Designation: On October 1, 2018, a New Technology Add-on Payment (NTAP) went into effect for ZEMDRI. The NTAP designation is granted for new technologies that demonstrate substantial clinical improvement over current treatments and provides hospitals with a payment, in addition to the standard-of-care Diagnostic Related Group (DRG) reimbursement, of up to 50% of the cost of ZEMDRI when prescribed to Medicare patients in a hospital setting for a period of two to three years.
Other Corporate Milestones
- Strategic Review and Restructuring: On November 5, 2018, the Company announced a review of strategic alternatives to maximize shareholder value and a restructuring to preserve cash resources and reduce total expenses.
Third Quarter 2018 Financial Results
Cash Position: At September 30, 2018, Achaogen had $58.2 million in unrestricted cash, cash equivalents and short-term investments compared to $164.8 million at December 31, 2017.
Revenue: Achaogen reported ZEMDRI net product sales of $0.3 million for the three months ended September 30, 2018. The full commercial launch of ZEMDRI occurred on July 20, 2018 so there were no similar product sales in the same period in 2017. Contract revenue totaled $1.7 million for the third quarter of 2018 compared to $0.6 million for the same period in 2017. The increase in contract revenue during the third quarter was primarily related to the BARDA C-Scape contract. As of September 30, 2018, $7.6 million remains under the BARDA C-Scape contract and up to an additional $6.0 million may be available under BARDA contract options. All Achaogen contract revenue consisted of U.S. government and Gates Foundation funding for the research and development of product candidates.
Research and Development (R&D): R&D expenses in the third quarter of 2018 were $21.7 million, compared to $25.3 million reported for the same period in 2017. The decrease in R&D expenses during the quarter was primarily due to a decrease in personnel and facility related costs.
Selling, General and Administrative (SG&A): SG&A expenses in the third quarter of 2018 were $18.9 million, compared to $11.8 million for the same period in 2017. The increase in SG&A expenses during the quarter was primarily due to an increase in personnel and facility related costs.
Restructuring Expenses: Restructuring expenses in the third quarter of 2018 were $7.9 million. There were no restructuring charges for in the same period in 2017. Restructuring charges include severance and payroll related costs, stock-based compensation costs and net facility exit costs related to our corporate restructuring announced on July 26, 2018.
Warrants and Derivative Liabilities: Change in warrant and derivative liabilities for the third quarter of 2018 was a $4.9 million gain compared to a $6.8 million gain for the same period in 2017. The decrease was primarily due to the change in the estimated fair value, which decreased due to the change in our stock price.
Net Loss: Achaogen reported a net loss of $41.8 million for the third quarter of 2018, compared to a net loss of $29.9 million for the same period in 2017. Diluted net loss was $1.02 per share for the third quarter of 2018, compared to diluted net loss of $0.85 per share for the same period in 2017. As of September 30, 2018, there were approximately 46.0 million shares of common stock outstanding.
The Company will host a conference call and webcast today at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. To participate by telephone, please dial 866-952-8559 (domestic) or 785-424-1745 (international); conference ID: ACHAOGEN. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.achaogen.com. The archived audio webcast will remain available on the Company's website for 30 days following the conference call.
Achaogen is a biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen's first commercial product is ZEMDRI, for the treatment of adults with complicated urinary tract infections, including pyelonephritis. The Achaogen ZEMDRI program was funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). The Company is currently developing C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination, which is also supported by BARDA. C-Scape is investigational, has not been determined to be safe or efficacious, and has not been approved for commercialization. For more information, visit the Achaogen website at www.achaogen.com.
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential uses and advantages of ZEMDRI (plazomicin), launch metrics for ZEMDRI, the approval of plazomicin by the EMA, the outcome of Achaogen’s strategic review, Achaogen’s expectations regarding the timing and impact of its restructuring, Achaogen’s strategic and commercial objectives and the Achaogen pipeline of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Achaogen's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties that the strategic review may not be successful, the risks and uncertainties of commercialization and gaining market acceptance, uncertainties inherent in the development process, the risks and uncertainties of the regulatory approval process, the risk when bacteria will evolve resistance to ZEMDRI, Achaogen’s reliance on third-party contract manufacturing organizations to manufacture and supply ZEMDRI, its product candidates and certain raw materials used in the production thereof and the risk that Achaogen's proprietary rights may be insufficient to protect ZEMDRI, its technologies and product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Achaogen business in general, see Achaogen’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 27, 2018, and its Quarterly Report on Form 10-Q filed on November 8, 2018. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances, or otherwise.
Investor and Media Contact:
Source: Achaogen, Inc.
© 2018 Achaogen, Inc. All Rights Reserved.
|Condensed Consolidated Statement of Operations|
|(in thousands except share and per share data)|
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|Product revenue, net||$||291||$||—||$||291||$||—|
|Cost of sales||11||—||11||—|
|Research and development||21,732||25,316||89,572||66,113|
|Selling, general and administrative||18,937||11,805||54,484||27,415|
|Total operating expenses||48,624||37,121||152,011||93,528|
|Loss from operations||(46,626||)||(36,544||)||(145,308||)||(84,222||)|
|Change in warrant and derivative liabilities||4,865||6,773||6,909||(3,957||)|
|Loss on debt extinguishment||—||—||(819||)||—|
|Other income, net||405||604||1,563||1,114|
|Net loss per common share|
|Weighted-average shares used to calculate net loss per common share|
|Condensed Consolidated Balance Sheets|
|September 30, 2018||December 31, 2017|
|Cash and cash equivalents||$||55,635||$||145,219|
|Trade and contract receivables, net||1,981||1,357|
|Prepaids and other current assets||6,348||6,367|
|Total current assets||67,518||178,406|
|Property and equipment, net||15,754||14,810|
|Other long-term assets||6,158||—|
|Liabilities, contingently redeemable common stock and stockholders’ equity|
|Loan payable, current portion||—||12,500|
|Total current liabilities||26,553||36,903|
|Loan payable, long-term||24,773||9,457|
|Derivative liability, long-term||—||686|
|Commitments and contingencies|
|Contingently redeemable common stock||10,000||10,000|
|Common stock, $0.001 par value, 290,000,000 shares authorized at September 30, 2018 and December 31, 2017; 45,967,093 and 42,515,015 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively||46||42|
|Preferred stock, $0.001 par value, 10,000,000 shares authorized and zero shares issued and outstanding at September 30, 2018 and December 31, 2017||—||—|
|Accumulated other comprehensive loss||—||—|
|Total stockholders’ equity||24,787||121,962|
|Total liabilities, contingently redeemable common stock and stockholders’ equity||$||97,301||$||197,071|